Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2013

01.01.2013 | Neurophthalmology

Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids

verfasst von: Gema Rebolleda, Marta Pérez-López, Pilar Casas-LLera, Inés Contreras, Francisco José Muñoz-Negrete

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate the visual and anatomic outcomes after systemic steroid treatment in non-arteritic anterior ischemic optic neuropathy (NAION).

Methods

Ten eyes from ten patients diagnosed with NAION and treated during the acute phase with 80 mg daily, tapering-down dose of corticosteroids were compared with a non-contemporary cohort of 27 patients that received no treatment. The visual outcomes of treated and untreated group were compared. Patients underwent complete ophthalmic examination including determination of Snellen visual acuity (VA), visual fields (VFs) (standard automated perimetry, Swedish Interactive Testing Algorithm 24–2 strategy), and optical coherence tomography (OCT) scanning of the optic nerve head at diagnosis, 6–8 weeks and 6 months after presentation.

Results

No statistical differences were found between steroid-treated and untreated NAION for the median change in VA (Mann–Whitney P = 0.28), median change in VF mean deviation (MD) and median change in VF pattern standard deviation (PSD) (Mann–Whitney P = 0.213 and P = 0.07 respectively). Statistical analysis showed no differences when comparing average RNFL loss (P = 0.871) and RNFL loss for superior, nasal, inferior and temporal optic disc quadrants between both groups. Complications occurred in three of the ten treated patients (30%); in one of them, steroid therapy had to be discontinued. Another two patients developed a NAION in their fellow eye after 2 and 3 months while on low-dose prednisone. No complications developed in the control group. The study was interrupted early due to a significantly higher rate of complications observed in the treated group (P = 0.002)

Conclusion

High-dose systemic steroid treatment did not show any beneficial effect in visual and anatomic outcomes when given during the acute phase of NAION. Furthermore, it caused serious complications in a third of the patients treated.
Literatur
2.
Zurück zum Zitat Atkins E, Bruce B, Newman N, Biousse V (2010) Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 55:47–63PubMedCrossRef Atkins E, Bruce B, Newman N, Biousse V (2010) Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 55:47–63PubMedCrossRef
3.
Zurück zum Zitat Bonamour G (1966) Apropos de pseudo-papillites vasculaire. Bull Soc Ophtalmol Fr 79:846 Bonamour G (1966) Apropos de pseudo-papillites vasculaire. Bull Soc Ophtalmol Fr 79:846
4.
Zurück zum Zitat Georgiades G, Konstas P, Stangos N (1966) Reflexions issues de l’etude de nombreaux cas de pseudo-papillite vasculaire. Bull Soc Ophtalmol Fr 79:506–536 Georgiades G, Konstas P, Stangos N (1966) Reflexions issues de l’etude de nombreaux cas de pseudo-papillite vasculaire. Bull Soc Ophtalmol Fr 79:506–536
5.
Zurück zum Zitat Haas A, Walzl M, Jesenik F, Walzl B, Berghold A, Berglöff J, Feigl B, Faulborn J (1997) Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 235(1):14–19PubMedCrossRef Haas A, Walzl M, Jesenik F, Walzl B, Berghold A, Berglöff J, Feigl B, Faulborn J (1997) Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 235(1):14–19PubMedCrossRef
6.
Zurück zum Zitat Kajiwara K, Tsubota K, Hara Y (1990) High dose urokinase thrombolysis and stellate ganglion block for anterior ischemic neuropathy. Fola Ophthalmol Jpn 41(1):59–64 Kajiwara K, Tsubota K, Hara Y (1990) High dose urokinase thrombolysis and stellate ganglion block for anterior ischemic neuropathy. Fola Ophthalmol Jpn 41(1):59–64
7.
Zurück zum Zitat Kollarits CR, McCarthy RW, Corrie WS, Swann ER (1981) Norepinephrine therapy of ischemic optic neuropathy. J Clin Neuroophthalmol 1(4):283–288PubMed Kollarits CR, McCarthy RW, Corrie WS, Swann ER (1981) Norepinephrine therapy of ischemic optic neuropathy. J Clin Neuroophthalmol 1(4):283–288PubMed
8.
Zurück zum Zitat Levin LA (2007) Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 42(3):403–408PubMedCrossRef Levin LA (2007) Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 42(3):403–408PubMedCrossRef
9.
Zurück zum Zitat Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246(7):1029–1046PubMedCrossRef Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246(7):1029–1046PubMedCrossRef
10.
Zurück zum Zitat Contreras I, Noval S, Rebolleda G, Muñoz-Negrete FJ (2007) Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography. Ophthalmology 114(12):2338–2344PubMedCrossRef Contreras I, Noval S, Rebolleda G, Muñoz-Negrete FJ (2007) Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography. Ophthalmology 114(12):2338–2344PubMedCrossRef
11.
Zurück zum Zitat Foulds WS (1970) Visual disturbances in systemic disorders: optic neuropathy and systemic disease. Trans Ophthalmol Soc UK 89:125–146PubMed Foulds WS (1970) Visual disturbances in systemic disorders: optic neuropathy and systemic disease. Trans Ophthalmol Soc UK 89:125–146PubMed
12.
Zurück zum Zitat Hayreh SS (1974) Anterior ischaemic optic neuropathy. III. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol 58(12):981–989PubMedCrossRef Hayreh SS (1974) Anterior ischaemic optic neuropathy. III. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol 58(12):981–989PubMedCrossRef
13.
Zurück zum Zitat Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K, Ischemic Optic Neuropathy Decompression Trial Research Group (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134(3):317–328PubMedCrossRef Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K, Ischemic Optic Neuropathy Decompression Trial Research Group (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134(3):317–328PubMedCrossRef
Metadaten
Titel
Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids
verfasst von
Gema Rebolleda
Marta Pérez-López
Pilar Casas-LLera
Inés Contreras
Francisco José Muñoz-Negrete
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2013
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-012-1995-7

Weitere Artikel der Ausgabe 1/2013

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.